Clinica Baviera - Asset Resilience Ratio
Clinica Baviera (CBAV) has an Asset Resilience Ratio of 14.23% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CBAV PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Clinica Baviera's Asset Resilience Ratio has changed over time. See CBAV net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Clinica Baviera's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CBAV stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €31.63 Million | 14.23% |
| Total Liquid Assets | €31.63 Million | 14.23% |
Asset Resilience Insights
- Moderate Liquidity: Clinica Baviera has 14.23% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Clinica Baviera Industry Peers by Asset Resilience Ratio
Compare Clinica Baviera's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Microba Life Sciences Ltd
AU:MAP |
Diagnostics & Research | 11.53% |
|
Immunovia publ AB
ST:IMMNOV |
Diagnostics & Research | 83.99% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Clinica Baviera (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Clinica Baviera.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.42% | €28.44 Million ≈ $33.25 Million |
€211.95 Million ≈ $247.80 Million |
-10.62pp |
| 2023-12-31 | 24.03% | €42.93 Million ≈ $50.19 Million |
€178.64 Million ≈ $208.85 Million |
-1.94pp |
| 2022-12-31 | 25.98% | €38.99 Million ≈ $45.58 Million |
€150.10 Million ≈ $175.49 Million |
+1.86pp |
| 2021-12-31 | 24.12% | €32.27 Million ≈ $37.73 Million |
€133.81 Million ≈ $156.44 Million |
+1.84pp |
| 2020-12-31 | 22.28% | €26.94 Million ≈ $31.49 Million |
€120.92 Million ≈ $141.37 Million |
+19.75pp |
| 2019-12-31 | 2.53% | €2.57 Million ≈ $3.00 Million |
€101.56 Million ≈ $118.74 Million |
-8.03pp |
| 2018-12-31 | 10.56% | €5.89 Million ≈ $6.89 Million |
€55.83 Million ≈ $65.27 Million |
-1.55pp |
| 2017-12-31 | 12.11% | €6.54 Million ≈ $7.64 Million |
€53.99 Million ≈ $63.12 Million |
-4.57pp |
| 2016-12-31 | 16.68% | €7.80 Million ≈ $9.12 Million |
€46.77 Million ≈ $54.68 Million |
-1.70pp |
| 2015-12-31 | 18.38% | €8.52 Million ≈ $9.97 Million |
€46.38 Million ≈ $54.22 Million |
-2.54pp |
| 2014-12-31 | 20.92% | €10.26 Million ≈ $11.99 Million |
€49.04 Million ≈ $57.33 Million |
-0.99pp |
| 2013-12-31 | 21.91% | €10.58 Million ≈ $12.37 Million |
€48.28 Million ≈ $56.44 Million |
+20.59pp |
| 2007-12-31 | 1.32% | €596.82K ≈ $697.75K |
€45.25 Million ≈ $52.90 Million |
-0.03pp |
| 2006-12-31 | 1.35% | €585.35K ≈ $684.34K |
€43.39 Million ≈ $50.73 Million |
-- |
About Clinica Baviera
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmol… Read more